Zobrazeno 1 - 5
of 5
pro vyhledávání: '"KAZUKI HASHIMOTO"'
Autor:
Mioko, Matsuo, Shingo, Baba, Kazuki, Hashimoto, Takuro, Isoda, Yoshiyuki, Kitamura, Ryunosuke, Kogo, Rina, Jiromaru, Takahiro, Hongo, Tomomi, Manako, Takashi, Nakagawa
Publikováno v:
Anticancer Research. 43:183-190
Differentiated thyroid cancer (DTC) has a good prognosis, except in the case of patients with radioiodine therapy (RIT)-refractory cancer. However, since DTC is essentially a slowly progressing cancer, it is usually judged to be a DTC with a poor pro
Autor:
KAZUKI HASHIMOTO, RYUJI YASUMATSU, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, HIDEOKI URYU, TORAHIKO NAKASHIMA, AKIHIRO TAMAE, RISA TANAKA, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKAMASA YOSHIDA, TAKASHI NAKAGAWA
Publikováno v:
Anticancer Research. 42:981-989
The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear.We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The ex
Autor:
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, HIDEOKI URYU, TORAHIKO NAKASHIMA, AKIHIRO TAMAE, RISA TANAKA, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKAMASA YOSHIDA, TAKASHI NAKAGAWA
Publikováno v:
In Vivo
Background/Aim: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment wi
Autor:
MIOKO MATSUO, RYUJI YASUMATSU, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, TAKAHIRO WAKASAKI, KAZUKI HASHIMOTO, RINA JIROMARU, TOMOMI MANAKO, TAKASHI NAKAGAWA
Publikováno v:
In Vivo
Background/Aim: A long-term effect has been confirmed in clinical practice since the introduction of nivolumab for treating various malignant tumors. A similar phenomenon is speculated to occur in head and neck cancer; however, details remain unclear
Autor:
Mayuko Miki, Koichi Hirokaga, Misao Soyama, Takuma Onoe, Kazuki Hashimoto, Koji Matsumoto, Minori Arase, Hideki Sakai, Meiko Nishimura, Shintaro Takao, Kaori Tane, Sayuri Watanabe
Publikováno v:
Anticancer Research. 39:4379-4383
Background/aim Dose-dense doxorubicin and cyclophosphamide (ddAC) followed by dose-dense paclitaxel (ddP) (ddAC-P) has improved disease-free survival of patients with breast cancer. The aim of this study was to evaluate the safety and relative dose i